Chelated Minerals and Limestone Particle Sizes on Performance and Bone Quality of Brown-Egg Layers

This study aimed to evaluate productive performance, egg quality, and bone quality of commercial brown-egg layers fed diets containing organic and inorganic minerals and three limestone particle sizes. A total of 288 birds at 64 weeks of age were distributed in a completely randomized design in a 2 × 3 factorial arrangement (two mineral sources and three limestone particle sizes) and eight replicates. The experiment lasted 112 days, divided into four periods. The following treatments were tested: T1 = inorganic minerals + 100% fine limestone; T2 = inorganic minerals + 50% fine limestone + 50% coarse limestone; T3 = inorganic minerals + 100% coarse limestone; T4 = inorganic + organic minerals + 100% fine limestone; T5 = inorganic + organic minerals + 50% fine limestone + 50% coarse limestone; and T6 = inorganic + organic minerals +100% coarse limestone. There was no significant interaction effect between the studied factors on any of the variables. No significant effect of the types of mineral mixes or limestone particle sizes were observed on the performance, egg quality, or bone quality variables evaluated. In conclusion, organic or inorganic minerals associated with limestone in fine, medium, or coarse particle sizes can be used in diets for brown-egg layers without affecting their productive performance, egg quality, or bone quality.

Chelated Minerals and Limestone Particle Sizes on Performance and Bone Quality of Brown-Egg Layers

This study aimed to evaluate productive performance, egg quality, and bone quality of commercial brown-egg layers fed diets containing organic and inorganic minerals and three limestone particle sizes. A total of 288 birds at 64 weeks of age were distributed in a completely randomized design in a 2 × 3 factorial arrangement (two mineral sources and three limestone particle sizes) and eight replicates. The experiment lasted 112 days, divided into four periods. The following treatments were tested: T1 = inorganic minerals + 100% fine limestone; T2 = inorganic minerals + 50% fine limestone + 50% coarse limestone; T3 = inorganic minerals + 100% coarse limestone; T4 = inorganic + organic minerals + 100% fine limestone; T5 = inorganic + organic minerals + 50% fine limestone + 50% coarse limestone; and T6 = inorganic + organic minerals +100% coarse limestone. There was no significant interaction effect between the studied factors on any of the variables. No significant effect of the types of mineral mixes or limestone particle sizes were observed on the performance, egg quality, or bone quality variables evaluated. In conclusion, organic or inorganic minerals associated with limestone in fine, medium, or coarse particle sizes can be used in diets for brown-egg layers without affecting their productive performance, egg quality, or bone quality.(AU)

Genomic variation at the MDR1 promoter and P-glycoprotein expression and activity in AML patients.

Sequence variation at the proximal MDR1 promoter of 72 patients with acute myeloid leukemia (AML) was investigated and its association with P-glycoprotein (Pgp) expression and activity using flow cytometry were analyzed. Two variants were found: -129T/C and a non-described A/T substitution at position +68 of intron 1 in one patient. Three different genotypes were identified for single nucleotide polymorphism (SNP) -129T/C: 60 patients TT, 11 individuals TC, and 1 CC. No significant association was found between SNP variants and Pgp activity and expression, at protein level. Our data also suggested that an evaluation of MDR1 promoter polymorphisms is of uncertain prognostic value.

Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile.

Pomolic acid (PA) is a pentacyclic triterpene which has been previously described as active in inhibiting the growth of K562 cell line-originated from chronic myeloid leukemia (CML) in blast crisis-and its vincristine-resistant derivative K562-Lucena1. In this work, cells from CML patients were treated with PA and the apoptotic index was compared with the multidrug resistance (MDR) profile and clinical status of the patients. Our findings show that PA 12.5 microg/ml at 24 h (p = 0.000), at 48 h (p = 0.012) and at 72 h (p = 0.005) has a potent apoptotic index in CML cells as compared to mononuclear cells from healthy donors. PA was capable to induce apoptosis in cells from CML patients exhibiting functional MDR phenotype but not in P-glycoprotein expression. In addition, PA was effective in chronic as well as in blast phase of CML. Moreover, similar apoptotic index induced by PA was observed in low, intermediate and high-risk Sokal score as well as in samples from the group of patients with clinical resistance to interferon and/or imatinib and non-treated patients. These results suggest that PA may be an effective agent for the treatment of CML.

Comparison between anthracyclines and rhodamine-123 accumulation in chronic lymphoid leukemia: effect of cyclosporin A and verapamil.

Multidrug resistance in leukemic cells is associated with decreased drug accumulation. A resistant cell line and cells from 11 patients with chronic lymphoid leukemia B were used for the evaluation of intracellular accumulation of daunorubicin (DNR), idarubicin (IDA), epirubicin (EPI) and rhodamine-123 (Rh-123). Cyclosporin A (CSA) and verapamil were used to test their modulatory effects on anthracyclines and the fluorescent dye. In leukemic samples there was a tendency for a lower accumulation index in samples tested with Rh-123 as compared to anthracyclines. IDA was a poorer substrate to P-glycoprotein (Pgp) than two of its analogues, e.g. DNR and EPI. A good correlation (80%) was found between Rh-123 accumulation and Pgp expression by phosphatase-anti-alkaline phosphatase. A strict correlation (100%) was found between modulation by CSA of Rh-123 accumulation and immunoreactivity to Pgp. Two discordant results were seen suggesting that other mechanisms of resistance could be present. The Rh-123 accumulation test seems to give a better indication than anthracyclines, however, it is not selective and may allow the detection of other drug-transport pumps.

Interaction of cyclosporin A and etoposide. Clinical and in vitro assessment in blast phase of chronic myeloid leukaemia.

Combination chemotherapy has had a low impact on survival of blast crises in chronic myelogeneous leukaemia (CML) which may be due to drug resistance. This work attempted to correlate the clinical response and some experimental evidence for the MDR phenotype. Blast cells were positive for P-glycoprotein using APAAP assay. In vitro tests showed that etoposide was partially toxic to blast cells when used alone but had its toxicity increased by nearly sixfold when combined with cyclosporin A (CSA). The patient responded poorly to treatment with etoposide combined with mitoxantrone and high-dose ara-c. However, when etoposide was associated with CSA, this patient returned to the chronic phase reinforcing our in vitro studies. Because no serious toxicity was seen clinically, we are inclined to consider the circumvention protocol an useful strategy to treat blast crises of CML.

Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide.

Alternative therapy for refractory leukemic patients is being increasingly adopted. Circumvention of multidrug resistance represents a strategy that has been taken into account when conventional chemotherapy failed. In this work a group of 15 refractory, heavily pretreated, patients was enrolled in a circumvention protocol including etoposide (ETO) and cyclosporin A (CSA). All patients received etoposide prior to this schedule. Toxicity to circumvention protocol was acceptable and only one serious side-effect was observed. Two hematological clinical responses were seen, both of which were positive to P-glycoprotein immunostaining and exhibited in vitro modulation by CSA in cultures using the thymidine incorporation assay. Three out of four patients negative for P-glycoprotein achieved a minor response. Three out of six clinical failures were also negative for Pgp immunostaining one of which exhibited sinergistic effect between ETO and CSA. Our study suggests that hematological response to ETO and CSA association can be obtained in intensely pretreated leukemic patients. Several factors may affect the response such as clinical status before this therapy. Additionally, it also suggests that not all CSA effects on the combination ETO-CSA can be attributed to Pgp modulation.